Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Learn more about COPD to overcome the obstacle: Breathe better, Live more
- COPD Congress 2018

About Conference

Allied academies invites all the participants across the globe to attend the 5th International Congress on Chronic Obstructive Pulmonary Disease slated on June 25-26, 2018 in Amsterdam, Netherlands. 
Theme: Learn more about COPD to overcome the obstacle: Breathe better, Live more

Allied Academies was founded by Jim and JoAnn Carland and the headquarters is located in North Carolina in United States of America. It conducts several academic conferences each year in different locations with internet participation possibilities for those who are physically unable to attend the conferences. Conference registrants are eligible for the Accelerated Journal Review. To provide you with maximum outlets for your research, Allied Business Academies holds joint meetings of all its member academies. In 1994 they launched the Journal of the International Academy of Case Studies, which has become a leader in publishing classroom teaching cases in business.

Why to attend COPD Congress 2018?
COPD Congress 2018 gives an exciting opportunity to meet with like minded individuals and industry peers. Congress unite individuals from all different geographical areas who share a common discipline or field. Congress gives you the opportunity to converse with these individuals one-on-one about what they are really going after, and they may even give you guidance on how to enhance your own particular work. At conference you have the opportunity to get feedback on your work from individuals who have never seen it before and may provide new insight. Briefly it is an invest into yourself, your profession and your organization.
Many Chest Conferences have been organized throughout the year across the world and it has been noticed that “COPD” was the main topic of discussion.

Target Audience:

  •  Pulmonologists
  •  Allergologist
  •  Academicians
  •  Research Scholars
  •  Professors
  •  Medical Students
  •  Practitioners
  •  Physicians
  •  Nurses
  •  Clinical Researchers
  •  Business Entrepreneurs
  •  Software Developing Companies
  •  Medical Devices Companies
  •  Biomedical Companies
  •  Biotechnology Companies
  •  Data Management Companies
  •  Other Healthcare Professionals with an interest in COPD

Sessions / Tracks

Track 1: Acute Exacerbation of COPD

COPD exacerbations are also known as acute exacerbations which is a worsening of COPD symptoms. An acute exacerbation is defined as increased breath shortness, increased production of sputum. There are many causes of acute exacerbation are: Respiratory exacerbation, in which many bacteria (pathogens) and viruses, not only this but allergens, toxins and air pollution is also responsible for COPD. It can be prevented by vaccination against the pathogens and also by some agonists (long acting beta-adrenoceptor agonists (LABAs)), inhaled corticosteroids, antibiotics and antivirals.

Track 2: Genetics of COPD

COPD is a type of the lung disease and highly prevalent disorder that causes from the interplay of genetic susceptibility. It is found that not a single gene accounts for a major part of the expression but a polygenic model is responsible for gene control. The significant technological advances have been made in genetic evaluation of complex diseases, in COPD there is a deficiency of Alpha-1 Anti-trypsin (a rare inherited disorders). It can be influenced by environmental factors and cigarette smoking.

Track 3: Chronic Pulmonary Hypertension

Chronic Pulmonary hypertension is a type of increase blood pressure in the lungs arteries and right side of the heart.  Pulmonary hypertension symptoms include the breath shortness, chest pain and swelling of legs. In this hypertension, the pulmonary arterioles and capillaries become narrowed, destroyed and blocked, which makes the capillaries difficult to flow the blood through lungs.

Track 4: Prevention and management of COPD

COPD Patients faces difficulty in clearing their lungs; with dusts, bacteria and other pollutants presents in surrounding atmosphere/environment. In most cases, COPD are potentially preventable through decreasing the smoke exposure and improving air quality. COPD exacerbations, hospitalizations and death can be cured by Influenza vaccination. It is known that, there is no alternative cure for COPD, but the symptoms are curely treatable and its progression can be delayed. It can be managed by the reducing the risk factors and by preventing and treating the acute exacerbation and associated illness. Breathing may be supported by Noninvasive ventilation.

Track 5: Pathophysiology and Pathogenesis of COPD

The pathogenesis of COPD is that constant airflow restriction. Airspace inflammation appears to be diverse in vulnerable smokers and Chronic Inflammation includes a power of breathed in aggravations, for example, CD8+ T lymphocytes, neutrophils, and macrophages, B cells and macrophages together  when activated, these cells start a inflammatory cascade(tumor necrosis factor alpha) and prompts to structural changes. Airway rebuilding in COPD is an immediate consequence of the inflammatory response related with COPD and resulting in the narrowing of the airways. Chronic Inflammation may also be added by bacterial infection.

The diseases that includes under the COPD are: Chronic Bronchitis, Emphysema and COPD-Asthma overlap. Bronchitis causes inflammation and irritation of the airways in the lungs. Over time, this mucus plugs up airways and makes breathing difficult. Emphysema is a common type of COPD in which the lung’s air sacs become damaged and destroyed. This damaged area makes difficulty for the people with emphysema to expel air from their lungs. Asthma COPD Overlap Syndrome (ACOS) usually includes increased reversibility of airflow obstruction, systemic inflammation and eosinophilic bronchial

·         Pathology of Smoking

·         Chronic Pulmonary Hypertension

·         Chronic Pulmonary Rehabilitation

·         Alpha-1 antitrypsin(AAT) deficiency

Track 6: Lung cancer and its function

Lung cancer is a lung tumor that is malignant, which is caused by uncontrolled cell growth in the lung’s tissues. It is also known as lung carcinoma, and the growth can spread beyond the lung by the process of metastasis into nearby tissue or other parts of the body. Patients with COPD are at high risk for both the development of primary lung cancer. There are two main types of lung cancer are small-cell lung carcinoma(sclc) and non-small-cell lung carcinoma(nsclc). The common symptoms for lung cancer are coughing (including coughing up blood), weight loss, shortness of breath, and chest pains. On the other hand, the chronic pulmonary disease could be a influencing factor in lung cancer, it increases the oxidative stress and results in DNA damage, chronic exposure,and increased cellular proliferation.

Track 7: COPD Epidemiology

COPD Epidemiology is the review and investigation of the examples, causes, and impacts of Chronic obstructive pulmonary disease in the population. According to the World Health Organization, COPD is the fourth foremost cause of death in the world, with almost 2.75 million deaths per annum, or 4.8% of deaths. In France, the mortality rate is approximately 40 deaths per 100,000 populations. At one time, COPD was more regular in men, but since of expanded tobacco use among ladies in high-wage nations and the higher danger of introduction to indoor air contamination in low-wage nations, this disease affects men and women almost equally.

Track 8: Risks of COPD and Cardiovascular Diseases

Chronic obstructive pulmonary disease (lung disease) and cardiovascular disease (heart disease) both share tobacco (smoking) as a major risk factor. Cardiovascular Disease significantly contributes to both mortality and morbidity in COPD. The other risk factors which are responsible for both COPD and Cardiovascular disease that includes:

·         a sedentary lifestyle contribute to the natural history of each of these conditions. Novel mechanisms are involved in the pathology and genetics of cardiovascular disease, and these may play an important role in driving the risks associated with COPD.

Track 9: Diagnostic Evaluation of COPD

The detection and diagnosis of COPD can be evaluated by performing the following tests: Spirometry, CT Scan, Chest X-ray, Arterial blood gas analysis, Severity, complete blood count, transthoracic ultrasonography and Lung function tests. Spirometry measures the amount of airflow obstruction present and is generally done after the use of a bronchodilator. An Arterial blood gas test measures the oxygen level in blood and the result can show how severe COPD is and whether patient need oxygen therapy. The differential diagnosis is also performed for testing the asthma, congestive heart failure and pulmonary embolism.

Track 10: Co-morbidities and COPD

Comorbidities and chronic obstructive pulmonary disease (COPD) are ubiquitous. Comorbidities such as coronary artery disease, diabetes mellitus, osteoporosis, hypertension and muscle weakness are commonly seen in the person with Chronic obstructive pulmonary disease. Smoking of tobacco is a common factor for many of these comorbidities and COPD, making it tough to draw conclusions about the relationship between COPD and these comorbidities including Lung Cancer. Pneumonia occurs when bacteria enter the lungs; which can weaken the lungs by creating an infection. This can lead to continuous illness and this downward spiral can lead to a rapid deterioration of health in COPD patient. Respiratory Insufficiency is a major complication of Chronic obstructive pulmonary disease.

Market Analysis

Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term used to describe obstructive lung diseases including emphysema, chronic bronchitis, refractory asthma and some forms of bronchiectasis. This disease is characterized by shortness of breath and cough with sputum production.

Importance & Scope
COPD Congress 2018 will be the best platform for all the Pulmonologists, Allergologist, Academicians, Research Scholars, Professors, Medical Students who are working in this field to exchange their knowledge related to COPD & Pulmonology Research. This international event is an effort to understand the underlying biological procedures which are amended to increase effectiveness, precision, survivability and quality of life.
Specialists will clarify how another era of treatment alternatives gives patients new trust in the battle against COPD.
Geologically, the worldwide COPD research market is grouped mainly at; United Kingdom, Netherlands, United States, Austria, Germany, Europe, Asia-Pacific, Middle East, Japan, and Africa. 

Why Amsterdam?
Amsterdam is the capital and most populous municipality of the Kingdom of the Netherlands.

Conference Highlights

  • Chest
  • Lung and its Functions
  • Chronic Obstructive Pulmonary Disease
  • COPD: Sign and Symptoms
  • Cause of COPD
  • Pathophysiology of COPD
  • COPD and Co-morbidities
  • COPD Diagnosis and Diagnostics
  • COPD Epidemiology
  • Advancement in Lung Surgeries
  • COPD Prevention and Management
  • COPD and Lung Cancer
  • Genetics of COPD
  • Therapies for COPD
  • COPD Exacerbation
  • Depression and Anxiety in COPD
  • COPD Health Care
  • COPD Complications
  • Drugs Acting on COPD

Why to attend COPD Congress 2018??
COPD Congress 2018 gives an exciting opportunity to meet with like-minded individuals and industry peers. Congress unites individuals from all different geographical areas who share a common discipline or field. Congress gives you the opportunity to converse with these individuals one-on-one about what they are really going after, and they may even give you guidance on how to enhance your own particular work. At conference you have the opportunity to get feedback on your work from individuals who have never seen it before and may provide new insight. Briefly it is an invest into yourself, your profession and your organization.

Target Audience
COPD Congress 2018 welcomes the Pulmonologists, Cardiologists, Academicians, Research Scholars, Professors, Medical Students, Practitioners, Physicians, Nurses, Clinical Researchers, Business Entrepreneurs, Software Developing Companies, Medical Devices Companies, Biomedical Companies, Biotechnology Companies, Data Management Companies and Other Healthcare Professionals with an interest in COPD to be a part of it.

Major COPD Research Associations
American Academy Of Allergy, Asthma & Immunology
American Association For Respiratory Care
Allergy/Asthma Information Association
American Lung Association
American Thoracic Society
Asian Pacific Society Of Respirology
Association Argentina De Medicina Respiratoria
Australian Lung Foundation
Association Of Bulgarians With Bronchial Asthma (Abba)
Asthma Society Of Canada
Asthma and Allergy Foundation of America
Asthma UK
Asthma and Allergy Association
Asthma Australia
Asthma and Respiratory Foundation NZ
Breathe The Lung Association 
British Lung Foundation
British Thoracic Society
Canadian Thoracic Society
Chest Foundation
Chinese COPD Patient Education Organization
COPD Canada
COPD Foundation
COPD Thoracic Society
COPD - Alert Support And Advocacy Group
COPD - International
COPD Patient Organization Of Vietnam
COPD Patients Club Kyrgyzstan
COPD Club Of Northern Thailand
COPD Patient Organization Of Vietnam
COPD Patients Club Kyrgyzstan
European Respiratory Society
European Lung Foundation
Emphysema Foundation For Our Right To Survive
Global Initiative For Chronic Obstructive Lung Disease
Infectious Diseases Society Of America
Irish Thoracic Society
Lung Cancer Europe
Lung Foundation Australia
National Emphysema Foundation
National Lung Health Education Program
National Heart, Lung And Blood Institute, National Institutes Of Health
Ontario Lung Association
Pulmonary Fibrosis Foundation
Pulmonary Fibrosis UK
Pulmonary Education &Research Foundation
Pulmonary Hypertension Association
Respiratory Health Association
The National Asthma Council Australia
The Canadian Lung Association
The International Association For The Study Of Lung Cancer

 


Major Universities
Australian National University, Australia
Charles Darwin University Casoria, Australia
Columbia University Medical  Center, United States
Curtin University Bentley, Australia
Dar Al Uloom University, Saudi Arabia
Harvard University, United States 
Imperial College London, United Kingdom
Iqbal Chest Centre, Bangladesh
Johns Hopkins University, Maryland
Leiden University, Netherlands
Linnaeus University, Sweden
Maastricht University, Netherlands
Macquarie University, Australia
McGill University, Canada
Medi7 Bent Leigh, Australia
Tufts University, United States
University of Birmingham, United Kingdom
University of California, San Francisco
University  of California Los Angeles, United States
University of Colorado Boulder, United States
University of Groningen, Netherlands
University of Pittsburgh, Pennsylvania
University of Toronto, Canada
University of Washington, United States


Major Companies
Abbott Laboratories, US
Allergan Pharmaceutical, US
Almirall, Spain
Amgen Pharmaceutical, US
Amphastar Pharmaceuticals Inc.
AstraZeneca, Switzerland
Bayer, Germany
Beacon Pharmaceuticals Ltd, UK
Biotie Therapies, Finland
Boehringer Ingelheim Pharmaceut Inc., Germany
Chiesi Pharmaceutical, Italy
Cipla Limited, India
Cohero Health, US
Forest Laboratories, US
Gecko Health, US
GlaxoSmithKline Pharmaceutical, UK
North Carolina Biotechnology Center, England
Novartis International AG, Switzerland
Panmira Pharmaceuticals LLC
Pearl Therapeutics Inc.
PhRMA, America
Pfizer, US
Probiomics Ltd., Australia
Roche Holding AG, Switzerland
Sunovion, US
Vectura Group, UK


Market Analysis Report
Worldwide COPD market is measured to as of now be worth $11.3 billion, and is estimate to achieve an estimation of $15.6 billion by 2019. A current market research concentrate distributed by Transparency Market Research (TMR), the international asthma and COPD market was worth USD 25,102.3 million in 2010, which is relied upon to achieve USD 26,965.5 million in 2017 alongside a CAGR figure of 1.03% over the estimated by 2017.
According to a survey done by WHO; Chronic obstructive pulmonary disease will be the third leading cause of death world-wide causing considerable health costs, in 2020. Globally, it is assessed that 3 million deaths were caused by the COPD in 2015 (that is, 5% of all deaths comprehensively in that year). Over 90% of COPD deaths happen in low and middle-income countries.
In the coming five years, the global asthma and COPD medicate market is relied upon to develop gradually and immovable. In 2010, the asthma tranquilize section commanded the general asthma and COPD advertise at USD 14,509.1 million. A lot of this development will be driven by a high number of new, more viable and advantageous items entering the market and telling more notable esteem contrasted with the treatments as of now in the market. 
The asthma and COPD Therapies Market 2015-2025 report examines the current and future pharmaceutical treatments for these two respiratory diseases. With detailed numbers for both asthma and COPD indicating development everywhere throughout the world, understanding the market and the medications accessible is essential for each one of those in fields identified with the division. Presently, North America drives the worldwide market for asthma and COPD medications and gadgets. North America was trailed by Europe as far as market capitalization. Be that as it may, North America and Europe is relied upon to miss out a portion of the piece of the overall industry to other rising local markets inferable from the expiry of a few patens of pharmaceutical organizations working in these areas.


To Collaborate Scientific Professionals around the World

Conference Date June 25-26, 2018
Speaker Oppurtunity
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Venue
&
Hospitality


Join The Discussion

Mail us at

For General Queries
copd@alliedconferences.org
For Registration
copd@alliedmeetings.org
More details about sponsorship:sponsors@alliedacademies.com

Authorization Policy


Copyright © 2017-2018 Allied Academies, All Rights Reserved.